Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period

Alfi Yasmina1,2, Anthonius de Boer1, Vera H.M. Deneer3, Patrick C. Souverein1 and Olaf H. Klungel1

1Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands, 2Department of Pharmacology & Therapeutics, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, Indonesia, and 3Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands

Keywords acute coronary syndrome, antiplatelet drugs, aspirin, clopidogrel, myocardial infarction

AIMS
The aims of the present study were to assess antiplatelet drug use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet nonpersistence.

METHODS
The present study was conducted in 4690 patients from the Utrecht Cardiovascular Pharmacogenetics cohort with a first MI between 1986 and 2010, who were followed for a maximum of 10 years. Medication use and event diagnosis were obtained from the Dutch PHARMO Record Linkage System. Antiplatelet drug users were classified as persistent users (gap between prescriptions ≤90 days), nonpersistent users (>90-day gap and no refills), and restarters (a new prescription after a >90-day gap). The association between potential determinants and antiplatelet nonpersistence was analysed using Cox regression.

RESULTS
The proportions of persistent users decreased from 84.0% at the 1-year follow-up to 32.8% at 10 years for any antiplatelet drug, and 77.3% to 27.5% for aspirin; and 39.0% to 6.4% for clopidogrel at 6 years. Most nonpersistent users restarted antiplatelet drugs later, leading to 89.3% overall antiplatelet drug users at 10 years after MI. Diabetes (hazard ratio [HR] 0.44; 0.32–0.60), hypertension (HR 0.77; 0.60–0.99), hypercholesterolaemia (HR 0.49; 0.39–0.62) and more recent MI diagnosis period (2003–2007: HR 0.69, 0.61–0.79; 2008–2010: HR 0.38, 0.19–0.77, compared to ≤ 2002 period) lowered the risk of antiplatelet nonpersistence, while vitamin K antagonist (VKA) comedication (HR 18.97; 16.91–21.28) increased this risk.

CONCLUSIONS
A large proportion of patients with a first MI still used antiplatelet drugs after 10 years. The frequent discontinuations during this time frame are expected to reduce the effectiveness of antiplatelet drugs as secondary prevention of cardiovascular diseases. Diabetes, hypertension, hypercholesterolaemia, VKA comedication and MI diagnosis period were determinants of antiplatelet nonpersistence.

DOI:10.1111/bcp.13139 © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- Antiplatelet drugs should be used life-long to prevent recurrent cardiovascular events after myocardial infarction (MI).
- Patterns of antiplatelet drug use after myocardial infarction have been studied only for short-term periods.

WHAT THIS STUDY ADDS

- This long-term drug persistence study showed a dynamic pattern of antiplatelet drug use after the first MI, with many discontinuations and restarts during follow-up.
- Diabetes, hypertension, hypercholesterolaemia, vitamin K antagonist comedication and calendar period of MI diagnosis were determinants of antiplatelet nonpersistence.
- Increased attention to the persistent use of antiplatelet drugs is important for lowering the risk of recurrent cardiovascular events.

Tables of Links

| TARGETS                        | LIGANDS       |
|--------------------------------|---------------|
| Enzymes [2]                   | Aspirin       |
| COX-1                          | Clopidogrel   |
| COX-2                          |               |
| G protein-coupled receptors [3]|               |
| P2Y_{12} receptor              |               |

These Tables list key protein targets and ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1], and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 [2, 3].

Introduction

Coronary heart diseases (CHD), particularly myocardial infarction (MI), is responsible for almost 1.8 million deaths annually in Europe. This mortality rate has decreased during the last three decades, owing to improvements in the acute treatment and secondary prevention of cardiovascular diseases (CVD). Nevertheless, death from CHD still constitutes 20% of all-cause mortality [4].

Antiplatelet drugs are given as acute treatment for acute coronary syndrome (ACS) and as secondary prevention for thrombotic events. Before 2002, only aspirin was used for secondary prevention. Since the publication of the European Society of Cardiology (ESC) guideline on the management of MI in 2002, aspirin in combination with a P2Y_{12}-inhibiting drug is recommended for secondary prevention. Aspirin should be used indefinitely, while the P2Y_{12}-inhibiting drug should be used for up to 1 year after an MI [5]. In the Netherlands, since 2006, the cost of prescriptions of the P2Y_{12}-inhibiting drug clopidogrel has been reimbursed by the public health-care system for 1 year after MI.

Several studies have been carried out on the use of antiplatelet drugs. The EuroAspire III survey on lifestyle, risk factors and drug use in patients with CHD was conducted in selected areas in 22 countries, and the results showed a relatively wide range of proportions (73.6–98.4%) of patients who used antiplatelet drugs at 6 months after the index CHD [6]. The Antiplatelet Therapy Observational Registry (APTOR) study in ACS patients who underwent percutaneous coronary intervention (PCI) in several hospitals in 14 European countries reported 32–94% dual antiplatelet drug users at 1 year [7].

Studies on antiplatelet drugs have seldom evaluated the persistence of drug use. The proportions of users reported have usually been based on antiplatelet drug use at a certain point in time, without providing information on the continuous use until that time point. Early discontinuation of antiplatelet drugs after CHD and PCI has been associated with an increased risk of stent thrombosis, recurrent MI, ischaemic stroke and cardiac death [8]. Therefore, persistence with antiplatelet treatment is critical in terms of the clinical outcome of these patients. Furthermore, none of the previous studies have followed the patients for a long period. In the present study, we took episodes of discontinuation into account, followed the patients for much longer (i.e. for a maximum of 10 years) and specifically studied MI patients, in whom the adverse effects of antiplatelet drug discontinuation might be more severe. Information on antiplatelet drug persistence after hospital discharge may be used to improve the secondary prevention of MI, and eventually will improve the outcome of MI patients.

The present study aimed to assess the patterns of antiplatelet drug use in MI patients by describing the proportions of persistent users, nonpersistent users and restarters over time. The changes in antiplatelet drug use before and after a recurrent ACS event following the first MI were also reported. As a secondary aim, the study evaluated determinants of nonpersistence with antiplatelet drugs after the first MI.
Methods

Data source and study population
The study cohort for the present retrospective study was recruited from the participants of the Utrecht Cardiovascular Pharmacogenetics (UCP) studies, who were enrolled from the Dutch population-based Pharmaco-Morbidity Record Linkage System (PHARMO) database. The PHARMO database links drug dispensing history from a representative sample of Dutch community pharmacies to the national registry of hospital discharge diagnoses. In the UCP studies, patients who had been dispensed an antihypertensive drug (low-ceiling diuretic, beta-blocker, angiotensin-converting enzyme inhibitor, calcium antagonist, angiotensin II type 1 receptor blocker, miscellaneous antihypertensive or combination of antihypertensive agents) and/or had hypercholesterolaemia (dispensed a cholesterol-lowering drug, or had a total cholesterol level of $>5.0$ mmol m$^{-3}$ or self-reported hypercholesterolaemia) were selected from the PHARMO database. Detailed descriptions on the designs of the UCP studies have been reported previously [9, 10]. The UCP studies received ethics approval from the Medical Ethics Committee of the University Medical Center Utrecht, the Netherlands.

The present study included UCP patients who had had their first hospitalization for an MI [International Classification of Diseases, Ninth Revision (ICD-9) code 410] during 1986–2009, been registered in the PHARMO database for at least 1 year before the index MI and were 18 years of age or older. Patients were followed from their hospital discharge for their first MI up to a maximum follow-up of 10 years, or until the patients left the database, or until 30 July 2010, whichever occurred first.

Data collection
Data on antiplatelet drug use were obtained from the PHARMO database. This database contains the name of the dispensed drug, Anatomical Therapeutic Chemical (ATC) code, dispensing date, code of the prescriber, amount of drug dispensed and daily dose. The duration of use of each dispensed drug can be calculated by dividing the number of dispensed drugs by the daily dose. The theoretical end date will be the dispensing date plus the estimated duration of use. Antiplatelet drug episodes were constructed based on the dispensed date and the theoretical end date. When an overlap between two episodes of an antiplatelet drug occurred, the number of overlapping days was added to the duration of the second episode.

Persistence and adherence to antiplatelet drug use
An MI patient was considered as an antiplatelet drug initiator if the drug was dispensed within 90 days after hospitalization for the first MI. Aspirin (ATC code B01AC06) and clopidogrel (ATC code B01AC04) were considered in the study. We did not include prasugrel or ticagrelor because the former had rarely been used and the latter was not yet commercially available during the study period.

The patterns of antiplatelet drug use after the first MI were assessed by classifying the antiplatelet drug initiators into persistent users, nonpersistent users and restarters. An antiplatelet drug initiator was considered a persistent user when the gap between consecutive antiplatelet drug episodes was $\leq90$ days. Otherwise, the patient was considered a nonpersistent user. An antiplatelet initiator who had a new antiplatelet drug episode after discontinuation of an antiplatelet drug for $>90$ days was considered a restarter. Patients who restarted an antiplatelet drug could have one or more antiplatelet drug episode(s) after the restart date. These patterns were evaluated for the use of any antiplatelet drug (ATC code B01AC), individual drugs (aspirin or clopidogrel) and dual antiplatelet therapy (DAPT) (the combination of aspirin and clopidogrel), at 6 months, 1 year and each additional year up to 10 years, or up to 6 years for clopidogrel and DAPT because of the shorter follow-up associated with these drugs. The pattern of use of clopidogrel was assessed in MI patients who had been discharged since 1998 because the marketing authorization of clopidogrel was issued on 15 July 1998 [11]. The pattern of DAPT use was assessed in MI patients who had been discharged since 2002 as the combination was indicated for ACS patients in the 2002 ESC guideline [5].

Adherence was calculated by dividing the sum of the durations of drug episodes by the elapsed time between the start date of the first drug episode and the end date of follow-up.

Determinants of antiplatelet drug nonpersistence
Potential determinants that might be associated with antiplatelet drug nonpersistence were evaluated. The factors considered were age, gender, diabetes, hypertension, hypercholesterolaemia, vitamin K antagonist (VKA) comedication, bleeding diagnosis during hospitalization, calendar period of MI diagnosis, and history of CAD, heart failure, atrial fibrillation and transient ischaemic attack/ischaemic stroke.

Pattern of antiplatelet drug use before and after recurrent ACS
Antiplatelet drug use before and after a recurrent ACS event following the first MI was also evaluated. The first recurrence of ACS event was defined as the occurrence of a recurrent MI (ICD-9 code 410) or unstable angina (ICD-9 code 411.1) in the year following the first MI; the second recurrence of ACS event was defined as the occurrence of a recurrent MI or unstable angina in the year following the first recurrence of ACS event, and so on. We only looked at the recurrent ACS events in the year following the previous event as CV events mostly occur within this period [8]. The dispensing of antiplatelet prescription in the 90 days before and 90 days after the first MI, and the first, second and third recurrence of ACS events was compared.

Statistical analysis
The proportions of persistent users, nonpersistent users and restarters were calculated by dividing the number of users and restarters at a certain time point by the number of initiators. These proportions were assessed for the use of any antiplatelet drug, individual antiplatelet drugs and DAPT. Kaplan–Meier curves were used to illustrate the distribution.
of nonpersistence and restart since the time of discontinuation. A stratified analysis of nonpersistence with any antiplatelet drug, aspirin and clopidogrel was conducted, based on calendar periods of the first MI diagnosis. The periods were ≤2002, 2003–2007 and 2008–2010. These periods were categorized based on the year when the ESC guidelines for MI [5, 12–14] were published. Adherence to antiplatelet drugs was reported as the average percentage, and the mean differences were analysed using the independent t-test. A stratified analysis of adherence was conducted based on age. Cox regression analysis was used to analyse the association between potential determinants and antiplatelet drug nonpersistence. VKA comedication and a bleeding diagnosis during hospitalization were included as time-varying variables.

The proportions of antiplatelet drug use in the 90 days before and 90 days after an event (the first MI or the recurrent ACS events) were calculated by dividing the number of antiplatelet drug users in that time period by the number of patients who had the event. The differences between the proportions of antiplatelet drug users before and after an event were analysed using McNemar’s chi-square test. The analyses in the present study were conducted using SPSS Statistics 20 (IBM, New York, USA) and R 3.1.3 (the R Foundation for Statistical Computing, Vienna, Austria) statistical software. A P-value less than 0.05 was considered significant.

Results

A total of 4690 MI patients were included in the study, with a median follow-up of 5.6 (interquartile range [IQR] 3.3–7.7) years. The baseline characteristics of the patients are shown in Table 1. The MI patients had an average age of 67.3 ± 11.6 years, most were men (63.7%) and a considerable proportion had a history of hypertension (72.7%) or hypercholesterolaemia (29.6%). 80.7% of patients started on any antiplatelet drug in the 90 days after discharge from hospital but less than a third started on DAPT (i.e. the combination of aspirin and clopidogrel). 11.1% patients had a first recurrence of ACS event over the following year, 20.0% of whom had a second recurrence of ACS event. Later, 28.2% of MI patients who had a second recurrence of ACS event experienced a third recurrence of ACS event.

Persistence with antiplatelet drug use

Figure 1 shows the proportion of antiplatelet drug users during follow-up. At the end of the first year, there were still 84.0% persistent users. The proportion of persistent users decreased over time, to 56.2% at 5 years and 32.8% at 10 years. Some of the nonpersistent users restarted antiplatelet drugs some time during the follow-up, resulting in 89.3% of antiplatelet drug users (combination of persistent users and restarters) at 10 years (Figure 1A). When the individual antiplatelet drugs were assessed, aspirin showed a similar pattern, starting with 82.6% of persistent users at 6 months, which decreased to 77.3% at 1 year, and the number was reduced further to 27.5% at 10 years. Some of the nonpersistent users restarted aspirin use, and there were 77.1% aspirin users at 10 years (Figure 1B).

| Characteristics | n (% of 4690 patients) |
|-----------------|------------------------|
| **Age, mean (standard deviation)** | 67.3 (11.6) |
| **Gender (male)** | 2987 (63.7) |
| **Antiplatelet drug users starting this treatment within 90 days after hospitalization (initiators)** | |
| Any antiplatelet drug | 3787 (80.7) |
| Aspirin | 2321 (49.5) |
| Clopidogrel | 1257 (33.4) |
| Aspirin monotherapy | 1489 (31.7) |
| Clopidogrel monotherapy | 595 (15.8) |
| Aspirin + clopidogrel | 641 (27.5) |
| **Disease history** | |
| Diabetes | 215 (4.6) |
| Hypertension | 3408 (72.7) |
| Hypercholesterolaemia | 1386 (29.6) |
| Coronary artery diseases | 716 (15.3) |
| Heart failure | 143 (3.0) |
| Atrial fibrillation | 150 (3.2) |
| Transient ischaemic attack/ ischaemic stroke | 108 (2.3) |
| **Bleeding** | 107 (2.3) |

*Only for myocardial infarction patients who were discharged after 1998 (n = 3761)

b Only for myocardial infarction patients who were discharged after 2002 (n = 2327)

In contrast with aspirin, clopidogrel showed a different pattern. At 6 months, 37.0% of patients discontinued clopidogrel use, and the proportion of persistent users was reduced steeply, to 39.0% at 1 year. Only a small proportion of patients continued using clopidogrel beyond 1 year. At 6 years after MI, 19.6% patients had restarted clopidogrel use, leading to 26.0% overall clopidogrel users (Figure 1C).

DAPT use followed the same pattern as clopidogrel (Figure 1D). The proportion of DAPT persistent users declined rapidly, from 56.8% at 6 months to 31.5% at 1 year. The DAPT nonpersistent users mostly continued their antiplatelet treatment with aspirin only (the cumulative proportion in 6 years was 23.7%), and a small proportion continued with clopidogrel only (the cumulative proportion in 6 years was 9.6%). The proportion of restarters for DAPT showed a small increase after 5 years.

Discontinuations and restarts of antiplatelet drugs after the first MI are also shown as Kaplan–Meier curves (Figure S1). The number of antiplatelet persistent users declined gradually over the years, but around 60% of those who discontinued had restarted again within 1 year after the discontinuation date. Aspirin users showed a similar gradual declining persistence pattern but with a slower increase in restarting after the discontinuation date. The percentage of clopidogrel persistent users declined more rapidly, to 39.0%
at 1 year, and less than 40% restarted gradually after the discontinuation date. Around 48% of these restarters had an ACS or PCI in the 90 days before the restart date (data not shown). As expected, DAPT persistent users showed a similar pattern to clopidogrel, with a small proportion restarting after discontinuation.

In those who became nonpersistent users within 6 months, 30% experienced a recurrent ACS event within 6 months after the discontinuation date. The median time interval between the discontinuation date and the first recurrence of ACS event in this group was 80 (IQR 34–150) days. In all patients who discontinued antiplatelet drugs, 15.8% of them experienced a first recurrence of ACS during the entire follow-up, and the median time interval between discontinuation date and the first recurrence of ACS event was 1101 (IQR 163–2236) days.

**Determinants of antiplatelet drug nonpersistence**

Stratification of persistent users by the calendar periods of MI diagnosis showed that the probability of antiplatelet discontinuation was significantly different between calendar periods ($P < 0.05$). There was an increase in antiplatelet persistence in patients whose MI diagnosis followed the publication of the updated ESC guidelines on MI in 2002–2003 and 2007–2008 (Figure 2). In Table 2, the corresponding HRs of the calendar periods are presented. VKA comedication (HR values ranged from 2.20 for clopidogrel to 18.97 for any antiplatelet drug) was associated with a higher risk of nonpersistence with any antiplatelet drug, aspirin, clopidogrel and DAPT. By contrast, diabetes (HR ranged from 0.44 to 0.52) and hypercholesterolaemia (HR ranged from 0.45 to 0.49) were both associated with a lower risk of nonpersistence with any antiplatelet drug and aspirin. Nonpersistence with clopidogrel was also associated with age [HR for every 10-year increase: 0.92; 95% confidence interval (CI) 0.87, 0.98], diabetes (HR 1.74; 95% CI 1.11, 2.73), hypercholesterolaemia (HR 1.43; 95% CI 1.12, 1.83) and previous CAD (HR 0.83; 95% CI 0.69, 0.98).

**Adherence to antiplatelet drug use**

The average adherence to antiplatelet drugs during the follow-up is shown in Figure S2. Average adherence to any...
Antiplatelet drug was high (86.3 ± 23.9%). Aspirin adherence was almost as high (79.0 ± 30.6%), while the adherence to clopidogrel was lower (38.6 ± 36.1%). The difference between the average adherence to aspirin and to clopidogrel was significant ($P < 0.01$). Patients who were 65 years of age or younger had an average adherence to antiplatelet drug of 89.2%, while those who were older than 65 years had an average of 84.3% (Figure S3).

### Figure 2
Kaplan–Meier curves for the discontinuation of antiplatelet drugs, stratified by calendar period of myocardial infarction diagnosis. (A) Any antiplatelet drug; (B) aspirin; (C) clopidogrel

Antiplatelet drug use before and after the first MI and recurrent ACS events
In general, there was an increase in antiplatelet drug use in the 90 days after an event compared with the use in the 90 days before the event, with the largest difference for the first MI (Figure 3). As expected, the increase in clopidogrel use for recurrent ACS events was larger than that for aspirin.

### Discussion
Persistence of the use of any antiplatelet drug after hospitalization for the first MI was relatively high in the Netherlands at 1 year. The proportion of persistent users decreased with each additional year following MI after the first year. At 10 years, the proportion of antiplatelet drug users was still fairly high (89.3%), due to a large proportion of restarters. A similar pattern was observed for aspirin. Clopidogrel persistence decreased rapidly in the first year, and the overall proportion of clopidogrel users was 26.0%
Several predictors for nonpersistence with antiplatelet drugs were identified. 63% antiplatelet drug use was recorded in the first year, 58% in the second year and 55% in the third year after the discontinuation date. Early antiplatelet discontinuation might be caused by drug intolerance, major bleeding, invasive procedures, comedications and patient-related factors. A discontinuation of antiplatelet drugs early after CHD and PCI might lead to a recurrent ACS event [8]. In the present study, the nonpersistent user proportion at 1 year was driven mostly by early discontinuation within 6 months. Indeed, the present study showed that in 30% of the patients who discontinued antiplatelet drugs within 6 months after the first MI, a recurrent ACS occurred within 6 months after the discontinuation date. Early antiplatelet discontinuation might be caused by drug intolerance, major bleeding, invasive procedures, comedications and patient-related factors [8, 15]. The reasons for discontinuation of antiplatelet drugs were not recorded in the present study.

The proportion of MI patients who persistently used antiplatelet drugs was relatively high in the first year, it was not optimal. A discontinuation of antiplatelet drugs early after CHD and PCI might lead to a recurrent ACS event [8]. In the present study, the nonpersistent user proportion at 1 year was driven mostly by early discontinuation within 6 months. Indeed, the present study showed that in 30% of the patients who discontinued antiplatelet drugs within 6 months after the first MI, a recurrent ACS occurred within 6 months after the discontinuation date. Early antiplatelet discontinuation might be caused by drug intolerance, major bleeding, invasive procedures, comedications and patient-related factors [8, 15]. The reasons for discontinuation of antiplatelet drugs were not recorded in the present study.

The proportion of antiplatelet drug users at 6 months after the first myocardial infarction (MI), and the 90 days before and after 90 days after the first, second and third recurrence of acute coronary syndrome (rec. ACS). ns, non-significant. *P < 0.05, **P < 0.01 at 6 years. DAPT and clopidogrel use patterns were similar. Several predictors for nonpersistence with antiplatelet drugs were identified.

While the proportion of MI patients who persistently used antiplatelet drugs was relatively high in the first year, it was not optimal. A discontinuation of antiplatelet drugs early after CHD and PCI might lead to a recurrent ACS event [8]. In the present study, the nonpersistent user proportion at 1 year was driven mostly by early discontinuation within 6 months. Indeed, the present study showed that in 30% of the patients who discontinued antiplatelet drugs within 6 months after the first MI, a recurrent ACS occurred within 6 months after the discontinuation date. Early antiplatelet discontinuation might be caused by drug intolerance, major bleeding, invasive procedures, comedications and patient-related factors [8, 15]. The reasons for discontinuation of antiplatelet drugs were not recorded in the present study.

The proportion of antiplatelet drug users at 6 months found in the present study was similar to that found in the EuroAspire III survey in the Netherlands [6]. However, the proportion of antiplatelet drug users at 1 year in the present study was higher than that found in the Netherlands Heart Foundation (NHF) study, which reported 58–65% antiplatelet drug use at 1 year after MI hospitalization [16]. This might be caused by differences in the methods used to calculate the number of users. The NHF study reported a point prevalence based on the dispensing of a prescription which period including 1 October each year.

Compared with the studies on antiplatelet drug use in other countries, the proportion of persistent antiplatelet drug use...
users in the Netherlands was lower. In a primary care study in
the UK, 85% patients were still using aspirin at 1 year after an
acute coronary event [17], as opposed to 77.3% in the
Netherlands. Another study in the UK reported a higher pro-
portion of clopidogrel persistent users (53.0–54.0%) at 1 year
after MI [18] compared with that in the Netherlands. How-
ever, a study in the USA showed a lower proportion of
clopidogrel persistent users, with only 31.5% of patients
remaining on clopidogrel at 1 year after acute MI or coronary
stenting [19].

The high nonpersistence of clopidogrel and DAPT is in
line with the results of the clinical trials and long-term observa-
tional studies leading to ESC guideline recommendations
on the use of antiplatelet drugs after coronary stenting for
ACS [20–23]. DAPT should be used for at least 1 month after
a bare metal stent (BMS) implantation, for at least 6 months
after a drug-eluting stent (DES) implantation and up to a
maximum of 1 year, or longer in patients with a high
cardiovascular and low bleeding risk, after which mono-
therapy with aspirin should be continued indefinitely
[23]. A previous study in Japan, conducted in patients who
underwent coronary revascularization between 2005 and
2007, showed that the percentage of patients using DAPT
was 67.3% in those receiving DES vs. 33.4% in those receiving
BMS at 1 year, and 48.7% vs. 24.3% at 5 years, respectively
[24]. However, there is no information available on the type
of stent used in the present study.

Stratification of calendar periods corresponding with the
publication dates of revised guidelines for MI demonstrated
that nonpersistence with antiplatelet drugs improved
during 2000–2010. The calendar period of MI diagnosis was
also shown to be an independent determinant of antiplatelet
nonpersistence. Concomitant VKA use was strongly associ-
ated with a higher risk of nonpersistence with antiplatelet
drugs. This finding was in line with that of a previous study
by Rossini et al., who showed that the use of an oral
anticoagulant was a predictor of discontinuation of aspirin,
clopidogrel and DAPT [8]. As the concomitant use of an anti-
platelet drug and an oral anticoagulant is associated with
bleeding [25], this combination should be avoided. However,
there are indications, such as for those with atrial fibrillation
undergoing coronary stenting, in whom the combination is
indicated [14]. In any antiplatelet drug users and in aspirin
users, diabetes and hypercholesterolaemia were significantly
associated with a lower risk of nonpersistence. This was
expected as these conditions are associated with a higher risk
of recurrent cardiovascular events. In clopidogrel users,
diabetes and hypercholesterolaemia were associated with a
higher risk of antiplatelet drug nonpersistence. Although this
was unexpected, it might be partly explained by the concern
of a pharmacokinetic interaction between atorvastatin and
clopidogrel in patients with hypercholesterolaemia [26],
and diabetes was reported as a predictor of insufficient anti-
platelet response to clopidogrel [27]. Patients with previous
CAD, who also have a higher risk for recurrent cardiovascu-
lar events, had a lower risk of clopidogrel nonpersistence
but a higher risk of DAPT nonpersistence. The latter might
have been confounded by bleeding events (major and
minor) as we did not include the time-varying bleeding
event variable in the analysis of DAPT use. We did not
have information on minor bleeding events, while more

severe bleeding events that needed hospitalization were
rare, occurring in 1% of patients.

The average adherence to any antiplatelet drug and
aspirin was relatively high, while clopidogrel adherence was
low. A study by Tuppin et al. [28], in France, showed an
approximately similar proportion (81.7%) of adherent users
of antiplatelet drugs (aspirin and clopidogrel) to that in our
study (78.9%). Another study, in Italy, showed a lower propor-
tion of adherent antiplatelet drug users (58.7%) [29].

The population of MI patients in our study were, on average,
younger than that in the Italian study. Younger patients tend
to be more adherent to treatment than older patients [28], as
also shown in the present study. However, even the older
patients in the present study showed a high adherence to
antiplatelet drugs.

When considering the results of the present study, some
limitations should be taken into account. We included pa-

tients who had previous conditions that might have affected
the use of antiplatelet drugs – e.g. those with hypertension,
hypercholesterolaemia, atrial fibrillation, stroke/transient
ischaemic attack and bleeding. We do not have information
on the reasons for antiplatelet discontinuation, or whether
the discontinuation was physician- or patient initiated. The
persistence of DAPT might be affected by the type of stent
used; however, the stent type is not available in the database.
Furthermore, the in-hospital use of drugs dispensed by the
hospital pharmacy was not recorded in our database, which
might have led to immeasurable time bias. However, as
patients were defined as persistent users when the gap
between consecutive drug episodes was ≤90 days, it is
unlikely that a misclassification of persistent users as nonper-
sistent users occurred as the length of stay in hospital was
rarely more than 90 days.

The strengths of the present study were that it had a
longer follow-up compared with the previous studies in this
field, and that it considered the proportions of persistent
users and restarters as opposed to point prevalence propor-
tions. The data source, the PHARMO dispensing database,
contained complete outpatient medication use data for
patients still registered in the database. The use of a dispens-
ing database, rather than patient/physician interview or recall,
in the study ensured a more reliable source of anti-
platelet exposure information. Furthermore, in contrast to
other countries, in the Netherlands low-dose aspirin for
CVD secondary prevention is available only on prescription
and is reimbursed, so the misclassification of aspirin expo-
sure due to over-the-counter dispensing was not an issue
in the present study. The choice of a 90-day gap as the
definition of nonpersistence has been used before. This
gap is equivalent to the length of a single chronic prescrip-
tion period in the Netherlands.

We showed that there is a need to improve persistence in
the use of antiplatelet drugs following MI. There should be
more attention to unjustified discontinuation of antiplatelet
drugs, particularly if it is initiated by patients. Future research
should be directed at monitoring antiplatelet drug use and
elucidating the reasons for antiplatelet drug discontinuation,
so that interventions can be developed to improve the persis-
tence with antiplatelet drugs.

In conclusion, there was a relatively high persistence with
any antiplatelet drug early after MI in this long-term follow-
up study in the Netherlands but this decreased in the years following the MI. Many patients restarted antiplatelet drugs during follow-up. However, in spite of the restart, it is important to be aware that the gap between discontinuation and restart is a critical period for the occurrence of recurrent CV events. Diabetes, hypertension, hypercholesterolaemia, VKA comedication and calendar period of MI diagnosis were important determinants of antiplatelet nonpersistence. Improvement is still needed in the secondary prevention of MI in the Netherlands.

Competing Interests

All authors have completed the Unified Competing Interest form and declared no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.

The UCP studies were funded by the Netherlands Heart Foundation and the Dutch Top Institute Pharma Mondriaan Project. The Division of Pharmacoepidemiology and Clinical Pharmacology employing authors A.d.B., O.H.K. and P.C.S. has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, the private-public-funded Top Institute Pharma, the EU Innovative Medicines Initiative (IMI) and the Respiratory Effectiveness Group. A.Y. received a scholarship for her doctorate degree from the Dikti-Neso Scholarship Award, from the Directorate General of Higher Education, Ministry of Education and Culture, Indonesia.

Contributors

A.Y., A.d.B. and O.H.K. designed this study, P.C.S. obtained and cleaned the data from the Dutch PHARMO Record Linkage System, and A.Y. conducted the statistical analysis and wrote the first draft of the manuscript. A.Y., A.d.B., O.H.K., V.H.M.D. and P.C.S. critically evaluated and approved the final manuscript.

References

1 Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 2016; 44: D1054–68.

2 Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–109.

3 Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 2015; 172: 5744–869.

4 Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014; 35: 2950–9.

5 Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809–40.

6 Kotseva K, Wood D, De Backer G, De Bacquier D, Pyörälä K, Keil U. EUROASPIRE III a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–37.

7 Zeymer U, James S, Berkenboom G, Mohacsi A, Iñiguez A, Coufal Z, et al. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev Cardiol 2013; 20: 218–28.

8 Rossini R, Capodanno D, Lettieri C, Musumeci G, Nijaradze T, Romano M, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107: 186–94.

9 van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, et al. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens 2009; 27: 61–8.

10 Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, van’t Slot R, et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010; 11: 1065–76.

11 European Medicines Agency. Plavix: EPAR – summary for the public. UK: European Medicines Agency, 2009.

12 Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28–66.

13 Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598–660.

14 Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–45.

15 Ferreira-González I, Marsal JR, Ribera A, Permyanyer-Miralda G, García-Del Blanco B, Martí G, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010; 122: 1017–25.

16 Vaartjes I, Koopman C, van Dis I, Visseren FLJ, Bots ML. Hart- en vaatziekten in Nederland 2013, cijfers over leefstijl, risicofactoren, ziekte en sterfte. Hartstichting: Den Haag, 2013.

17 Sáez MF, González-Pérez A, Johansson S, Nagy P, Rodriguez LA. Patterns of antiplatelet therapy in patients who have experienced an acute coronary event: descriptive study in UK primary care. J Cardiovasc Pharmacol Ther 2015; 20: 378–86.

18 Boggon R, van Staa TP, Timmis A, Hemingway H, Ray KK, Begg A, et al. Clopidogrel discontinuation after acute coronary
 syndromes: frequency, predictors and associations with death and myocardial infarction – a hospital registry–primary care linked cohort (MINAP-GPRD). Eur Heart J 2011; 32: 2376–86.

19 Wiederkehr D, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Corbelli J. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin 2009; 25: 2327–34.

20 Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584–91.

21 Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009–19.

22 Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998–1008.

23 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–619.

24 Watanabe H, Morimoto T, Natsuaki M, Furukawa Y, Nakagawa Y, Kadota K, et al. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. PLoS One 2015; 10: e0124314.

25 Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577–85.

26 Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251–63.

27 Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427–34.

28 Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A, Ricordeau P, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010; 103: 363–75.

29 Lenzi J, Rucci P, Castaldini I, Protonotari A, Di Pasquale G, Di Martino M, et al. Does age modify the relationship between adherence to secondary prevention medications and mortality after acute myocardial infarction? A nested case–control study. Eur J Clin Pharmacol 2015; 71: 243–50.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

http://onlinelibrary.wiley.com/doi/10.1111/bcp.13139/suppinfo.

**Figure S1** Kaplan–Meier curves for the discontinuation and restart of the following antiplatelet drugs: (A) any antiplatelet drug; (B) aspirin; (C) clopidogrel; and (D) DAPT aspirin and clopidogrel

**Figure S2** Average adherence to antiplatelet drugs

**Figure S3** Average adherence to antiplatelet drugs, stratified by age